Initial data from an ongoing Phase I/II study of HPK1 inhibitor NDI-101150 show clinical benefit in three patients with solid tumours, including one complete response in a patient with renal cell carcinoma.
Two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> six months) stable disease. NDI-101150 demonstrated an acceptable safety profile below 200mg/day, the identified non-tolerated dose.
The data were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.
“We’re pleased to share these first clinical data from our clinical trial of NDI-101150. We are encouraged by the preliminary efficacy we have seen thus far, which supports the potential of NDI-101150 to provide a meaningful therapeutic option for patients with solid tumours,” said Nathalie Franchimont, Chief Medical Officer of Nimbus. “HPK1 inhibition is an exciting approach because of its potential to activate not just T cells, as checkpoint inhibitors do, but also B cells and dendritic cells.”
The Phase I/II trial is a multicentre, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of NDI-101150 given as monotherapy or in combination with pembrolizumab in adults with advanced or metastatic solid tumours.
